- Accelerating the diagnostic pathway: Helping provide tools that shorten the time-consuming diagnostic pathway
- Improving disease monitoring: Putting forward a solution to measure and analyze meaningful data that reflects the patients’ individual disease progression
- Easing burden on patients: Bringing a patient-centered solution easing the burden for patients during the complex diagnosis and therapy pathway
- Maintaining quality of life: For Alzheimer’s patients and their families, it is crucial to maintain their quality of life while living with the disease. Also, behavioral disturbances related to Alzheimer’s (apathy, depression, anxiety, insomnia, etc.) pose an enormous challenge.
Combinostics’ cDSI and cMRI Applications, Part of the cNeuro Platform, Receive EC-certification Under the EU’s Medical Device Regulation (MDR)
cNeuro® cDSI™ and cNeuro cMRI™ achieve EC-certification under MDR, ensuring continued delivery of services to European customers.